Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Common Variable Immunodeficiency Medication

  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Dirk M Elston, MD  more...
 
Updated: Jun 02, 2016
 

Medication Summary

The goals of pharmacotherapy for common variable immunodeficiency (CVID) are to reduce morbidity and prevent complications. Treatment with rapamycin has been suggested, but this therapy awaits proper evaluation.[40] Rituximab has been used to treat associated hemolytic anemia and thrombocytopenia.[41] Additionally, Lin et al reported on the treatment of CVID-associated cutaneous granuloma using etanercept.[42]

Next

Immunoglobulins

Class Summary

Ig passively supplies recipients with a broad spectrum of IgG antibodies against bacteria, viruses, and parasites.

Immune globulin intravenous (Gamimune, Gammar-P, Sandoglobulin, Gammagard S/D)

 

Intravenous immune globulin neutralizes circulating myelin antibodies with anti-idiotypic antibodies. It down-regulates proinflammatory cytokines, including interferon-gamma. It blocks Fc receptors on macrophages and blocks the complement cascade. It suppresses inducer T and B cells and augments suppressor T cells. It also promotes remyelination and may increase CSF IgG levels by 10%.

Previous
 
Contributor Information and Disclosures
Author

Robert A Schwartz, MD, MPH Professor and Head of Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, Rutgers New Jersey Medical School; Visiting Professor, Rutgers University School of Public Affairs and Administration

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, New York Academy of Medicine, American Academy of Dermatology, American College of Physicians, Sigma Xi

Disclosure: Nothing to disclose.

Coauthor(s)

Rohit M Modak, MD, MBA Staff Physician, Department of Infectious Diseases, Virginia Hospital Center

Disclosure: Nothing to disclose.

Prema Modak, MD Physician, The Eye Center, Inc., Rockville, MD

Prema Modak, MD is a member of the following medical societies: American Academy of Ophthalmology

Disclosure: Nothing to disclose.

Specialty Editor Board

David F Butler, MD Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

David F Butler, MD is a member of the following medical societies: American Medical Association, Alpha Omega Alpha, Association of Military Dermatologists, American Academy of Dermatology, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Phi Beta Kappa

Disclosure: Nothing to disclose.

Jeffrey P Callen, MD Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Jeffrey P Callen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, American College of Rheumatology

Disclosure: Received income in an amount equal to or greater than $250 from: XOMA; Biogen/IDEC; Novartis; Janssen Biotech, Abbvie, CSL pharma<br/>Received honoraria from UpToDate for author/editor; Received honoraria from JAMA Dermatology for associate editor and intermittent author; Received royalty from Elsevier for book author/editor; Received dividends from trust accounts, but I do not control these accounts, and have directed our managers to divest pharmaceutical stocks as is fiscally prudent from Stock holdings in various trust accounts include some pharmaceutical companies and device makers for i inherited these trust accounts; for: Celgene; Pfizer; 3M; Johnson and Johnson; Merck; Abbott Laboratories; AbbVie; Procter and Gamble; Amgen.

Chief Editor

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Takeji Nishikawa, MD Emeritus Professor, Department of Dermatology, Keio University School of Medicine; Director, Samoncho Dermatology Clinic; Managing Director, The Waksman Foundation of Japan Inc

Disclosure: Nothing to disclose.

References
  1. Boileau J, Mouillot G, Gerard L, et al. Autoimmunity in common variable immunodeficiency: correlation with lymphocyte phenotype in the French DEFI study. J Autoimmun. 2011 Feb. 36(1):25-32. [Medline].

  2. Bergler-Czop B, Brzezinska-Wcislo L. Pyoderma gangrenosum in a patient with common variable primary immunodeficiency. Postepy Dermatol Alergol. 2013 Jun. 30(3):188-91. [Medline]. [Full Text].

  3. Simsek O, Ulusan K, Orhan A, Kiris T, Kocael A, Kocael P. Pyoderma gangrenosum with common variable immunodeficiency. Wounds. 2015 May. 27(5):129-33. [Medline].

  4. Arunachalam M, Sanzo M, Lotti T, Colucci R, Berti S, Moretti S. Common variable immunodeficiency in vitiligo. G Ital Dermatol Venereol. 2010 Dec. 145(6):783-8. [Medline].

  5. Alvarez-Cuesta C, Molinos L, Cascante JA, Soler T, Perez-Oliva N. Cutaneous granulomas in a patient with common variable immunodeficiency. Acta Derm Venereol. 1999 Jul. 79(4):334. [Medline].

  6. Krupnick AI, Shim H, Phelps RG, Cunningham-Rundles C, Sapadin AN. Cutaneous granulomas masquerading as tuberculoid leprosy in a patient with congenital combined immunodeficiency. Mt Sinai J Med. 2001 Sep-Oct. 68(4-5):326-30. [Medline].

  7. Mitra A, Pollock B, Gooi J, Darling JC, Boon A, Newton-Bishop JA. Cutaneous granulomas associated with primary immunodeficiency disorders. Br J Dermatol. 2005 Jul. 153(1):194-9. [Medline].

  8. Levine TS, Price AB, Boyle S, Webster AD. Cutaneous sarcoid-like granulomas in primary immunodeficiency disorders. Br J Dermatol. 1994 Jan. 130(1):118-20. [Medline].

  9. Pagnini I, Simonini G, Lippi F, Azzari C, Cimaz R. Cutaneous polyarteritis nodosa and common variable immunodeficiency: a previously unreported association. Clin Exp Rheumatol. 2012 Jan-Feb. 30(1 Suppl 70):S169. [Medline].

  10. Abdel-Naser MB, Wollina U, El Hefnawi MA, Habib MA, El Okby M. Non-sarcoidal, non-tuberculoid granuloma in common variable immunodeficiency. J Drugs Dermatol. 2006 Apr. 5(4):370-2. [Medline].

  11. van de Ven AA, van de Corput L, van Tilburg CM, et al. Lymphocyte characteristics in children with common variable immunodeficiency. Clin Immunol. 2009 Dec 11. [Medline].

  12. Wong GK, Huissoon AP. T-cell abnormalities in common variable immunodeficiency: the hidden defect. J Clin Pathol. 2016 May 6. [Medline].

  13. Cunningham-Rundles C. Autoimmune manifestations in common variable immunodeficiency. J Clin Immunol. 2008 May. 28 Suppl 1:S42-5. [Medline].

  14. Rezaei N, Wing J, Aghamohammadi A, et al. B-cell-T-cell activation and interaction in common variable immunodeficiency. Hum Immunol. 2010 Feb 4. [Medline].

  15. Abolhassani H, Gharib B, Shahinpour S, Masoom SN, Havaei A, Mirminachi B, et al. Autoimmunity in patients with selective IgA deficiency. J Investig Allergol Clin Immunol. 2015. 25(2):112-9. [Medline].

  16. Rezaei N, Aghamohammadi A, Siadat SD, et al. Serum bactericidal antibody responses to meningococcal polysaccharide vaccination as a basis for clinical classification of common variable immunodeficiency. Clin Vaccine Immunol. 2008 Apr. 15(4):607-11. [Medline].

  17. Lanio N, Sarmiento E, Gallego A, Carbone J. Immunophenotypic profile of T cells in common variable immunodeficiency: is there an association with different clinical findings?. Allergol Immunopathol (Madr). 2009 Jan-Feb. 37(1):14-20. [Medline].

  18. Castigli E, Wilson SA, Garibyan L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet. 2005 Aug. 37(8):829-34. [Medline].

  19. Schaffer AA, Salzer U, Hammarström L, Grimbacher B. Deconstructing common variable immunodeficiency by genetic analysis. Curr Opin Genet Dev. 2007 Jun. 17(3):201-12. [Medline].

  20. Neumann C, Grimbacher B. [Molecular basis of common variable immunodeficiency]. Dtsch Med Wochenschr. 2007 Apr 20. 132(16):885-7. [Medline].

  21. Salzer U, Chapel HM, Webster AD, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet. 2005 Aug. 37(8):820-8. [Medline].

  22. Finck A, Van der Meer JW, Schaffer AA, et al. Linkage of autosomal-dominant common variable immunodeficiency to chromosome 4q. Eur J Hum Genet. 2006 Jul. 14(7):867-75. [Medline].

  23. Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008 Jul 15. 112(2):277-86. [Medline].

  24. Aghamohammadi A, Farhoudi A, Moin M, et al. Clinical and immunological features of 65 Iranian patients with common variable immunodeficiency. Clin Diagn Lab Immunol. 2005 Jul. 12(7):825-32. [Medline].

  25. Kwong JC, Ward PB, Johnson PD. Cutaneous protothecosis in a patient with hypogammaglobulinemia. Med Mycol Case Rep. 2013 Jun 20. 2:132-3. [Medline]. [Full Text].

  26. Le Cleach L, Benchikhi H, Liedman D, Boumsel L, Wolkenstein P, Revuz J. [Hand-foot-mouth syndrome recurring during common variable deficiency]. Ann Dermatol Venereol. 1999 Mar. 126(3):251-3. [Medline].

  27. Khodadad A, Aghamohammadi A, Parvaneh N, et al. Gastrointestinal manifestations in patients with common variable immunodeficiency. Dig Dis Sci. 2007 Nov. 52(11):2977-83. [Medline].

  28. Lassoued K. [Humoral immune deficits and the skin]. Ann Dermatol Venereol. 1999 Mar. 126(3):215-22. [Medline].

  29. Boonyaleepun S, Boonyaleepun C, Schlactus JL. Effect of IVIG on the hair regrowth in a common variable immune deficiency patient with alopecia universalis. Asian Pac J Allergy Immunol. 1999 Mar. 17(1):59-62. [Medline].

  30. Kilic S, Ersoy F, Sanal O, Turkbay D, Tezcan I. Alopecia universalis in a patient with common variable immunodeficiency. Pediatr Dermatol. 1999 Jul-Aug. 16(4):305-7. [Medline].

  31. Sanjuán Álvarez M, Sánchez Zamora P, González Salvador Y, García Rueda A, Herrero Trujillano M, Rodríguez Bertos C. [Necrotising fasciitis in a patient with common variable immunodeficiency.]. Rev Esp Anestesiol Reanim. 2012 May 8. [Medline].

  32. Pujol RM, Nadal C, Taberner R, Diaz C, Miralles J, Alomar A. Cutaneous granulomatous lesions in common variable immunodeficiency: complete resolution after intravenous immunoglobulins. Dermatology. 1999. 198(2):156-8. [Medline].

  33. Green HA, Moschella S. Multiple invasive squamous cell carcinomas and common variable immunodeficiency. Arch Dermatol. 1992 Mar. 128(3):412-3. [Medline].

  34. Creamer D, McGregor JM, Hawk JL. Polymorphic light eruption occurring in common variable hypogammaglobulinaemia, and resolving with intravenous immunoglobulin therapy. Clin Exp Dermatol. 1999 Jul. 24(4):273-4. [Medline].

  35. Nijenhuis T, Klasen I, Weemaes CM, Preijers F, de Vries E, van der Meer JW. Common variable immunodeficiency (CVID) in a family: an autosomal dominant mode of inheritance. Neth J Med. 2001 Sep. 59(3):134-9. [Medline].

  36. Modrzewska K, Wiatr E, Langfort R, Oniszh K, Roszkowski-Sliz K. [Common variable immunodeficiency in a patient with suspected sarcoidosis]. Pneumonol Alergol Pol. 2009. 77(1):91-6. [Medline].

  37. Quinti I, Di Pietro C, Martini H, Pesce AM, Lombardi F, Baumghartner M, et al. Health related quality of life in common variable immunodeficiency. Yonsei Med J. 2012 May 1. 53(3):603-10. [Medline].

  38. Rezaei N, Siadat SD, Aghamohammadi A, et al. Serum Bactericidal Antibody Response One Year after Meningococcal Polysaccharide Vaccination in Patients with Common Variable Immunodeficiency. Clin Vaccine Immunol. 2010 Jan 27. [Medline]. [Full Text].

  39. Hanitsch LG, Löbel M, Mieves JF, Bauer S, Babel N, Schweiger B, et al. Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency. Vaccine. 2016 May 5. 34 (21):2417-23. [Medline].

  40. Simonson WT, Markovina S, Grossman WJ, et al. Common variable immunodeficiency with regulatory T-cell deficiency treated with rapamycin. Ann Allergy Asthma Immunol. 2009 Feb. 102(2):170-1. [Medline].

  41. Shabbat S, Aharoni J, Sarid L, Ben-Harush M, Kapelushnik J. Rituximab as monotherapy and in addition to reduced CHOP in children with primary immunodeficiency and non-Hodgkin lymphoma. Pediatr Blood Cancer. 2009 May. 52(5):664-6. [Medline].

  42. Lin JH, Liebhaber M, Roberts RL, Dyer Z, Stiehm ER. Etanercept treatment of cutaneous granulomas in common variable immunodeficiency. J Allergy Clin Immunol. 2006 Apr. 117(4):878-82. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.